Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe

FDA approves drug for severe asthma

Melissa Jenco, News Content Editor
November 05, 2015

The Food and Drug Administration (FDA) has approved a new drug for patients 12 years and older with severe asthma.

Nucala (mepolizumab), manufactured by GlaxoSmithKline, is a maintenance treatment for use with other asthma medications.

“This approval offers patients with severe asthma an additional therapy when current treatments cannot maintain adequate control of their asthma,” Badrul Chowdhury, M.D., Ph.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research, said in a news release.

The drug reduces levels of blood eosinophils and is administered every four weeks by an injection into the upper arm, thigh or abdomen.

Nucala was tested in three double-blind, randomized, placebo-controlled trials. Those taking the drug required fewer hospitalizations for asthma attacks and experienced a reduction in their daily oral corticosteroid dose, according to the FDA. However, they did not experience significant improvement in lung function measured by volume of air exhaled in one second.

Common side effects include headache, injection site reactions, back pain and weakness. Swelling of the face, mouth and tongue; dizziness; hives; breathing problems; rash and herpes zoster infections also can occur.

The FDA’s approval comes despite its Pulmonary-Allergy Drugs Advisory Committee’s decision in June to recommend the drug only for adults, saying there was not enough efficacy and safety data relating to children 12-17 years old.
Resources
  • FDA briefing document on Nucala
  • FDA Pulmonary-Allergy Drugs Advisory Committee meeting minutes regarding Nucala
  • Information for parents about asthma symptoms
  • Information for parents about asthma medications
  • Centers for Disease Control and Prevention asthma resources
Copyright © 2015, The American Academy of Pediatrics

Advertising Disclaimer »

Download PDF
Email News Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FDA approves drug for severe asthma
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
FDA approves drug for severe asthma
Melissa Jenco
November 05, 2015
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Digital Edition Current Issue
  • Latest Daily News
  • Archives
  • Collections
  • Columns
  • Advertising
  • Subscribe to AAP News Magazine
  • Terms of Use
  • Privacy Statement
  • FAQ
  • Contact Us
  • 2021 AAP Journals Catalog
  • Pediatrics
  • Pediatrics in Review
  • Hospital Pediatrics
  • NeoReviews
  • AAP Grand Rounds
  • AAP Career Center
  • shopAAP
  • AAP.org
  • AAP News
  • Visit AAP News on Facebook
  • Follow AAP News on Twitter
American Academy of Pediatrics

© 2021 American Academy of Pediatrics